🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial

  2. ABIRATERONE , DEGARELIX , Niraparib - capsule - 100 mg, RELUGOLIX , Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for Niraparib, Prednison acis 5 mg, Tabletten, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, TECHNETIUM (99MTC) COMPOUNDS, -, Abiraterone acetate - tablet - 250 mg

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  3. ABIRATERONE ACETATE, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, SYLVANT 400 mg powder for concentrate for solution for infusion, CABAZITAXEL, AMG 509, ABIRATERONE ACETATE, DOCETAXEL

    Amgen Technology (Ireland) UC

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  4. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  5. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Cancer Prevention Pharma (Ireland) Limited

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  6. ABIRATERONE, 177Lu-PNT2002, GALLIUM (68GA) GOZETOTIDE , ENZALUTAMIDE

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  7. ADSTILADRIN

    Ferring Pharmaceuticals A/S

    Intermediate risk, non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  8. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Hungary Kft.

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. ALPELISIB, ALPELISIB, ALPELISIB

    Cancer Prevention Pharma (Ireland) Limited

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  11. ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

    Novartis Ophthalmics Europe

    Hormone receptor positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  12. AMG 706

    Takeda Pharmaceuticals International AG

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  13. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  14. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  15. AZD8205, PACLITAXEL, DOXORUBICIN

    AstraZeneca AB

    B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

    phase 3 small molecule active

    1 trial

  16. Abemaciclib

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 3 small molecule active

    1 trial

  17. Abemaciclib, Lasofoxifene, Fulvestrant

    Pharma Mar S.A.

    Locally advanced or metastatic breast cancer

    phase 3 small molecule active

    1 trial

  18. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  19. Abraxane 5 mg/ml powder for dispersion for infusion., Paclitaxel 6 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    Gilead Sciences International Limited

    PD-L1-negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting

    phase 3 small molecule active

    1 trial

  20. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  21. Afinitor 5 mg tablets, PLACEBO

    Cancer Prevention Pharma (Ireland) Limited

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  22. Aflibercept

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  23. Aflibercept AVE0005

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  24. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources